Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: May 26, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,126,931

« Back to Dashboard

Which drugs does patent 9,126,931 protect, and when does it expire?


Patent 9,126,931 protects ALECENSA and is included in one NDA.

This patent has thirty-three patent family members in thirty countries.

Summary for Patent: 9,126,931

Title:Tetracyclic compound
Abstract: A compound represented by the general Formula (I) below, or a salt or solvate thereof, which is useful as an ALK inhibitor, and is useful for prophylaxis or treatment of a disease accompanied by abnormality in ALK, for example, cancer, cancer metastasis, depression or cognitive function disorder: ##STR00001## (meanings of the symbols that are included in the formula are as given in the specification).
Inventor(s): Kinoshita; Kazutomo (Kanagawa, JP), Asoh; Kohsuke (Kanagawa, JP), Furuichi; Noriyuki (Kanagawa, JP), Ito; Toshiya (Kanagawa, JP), Kawada; Hatsuo (Kanagawa, JP), Ishii; Nobuya (Kanagawa, JP), Sakamoto; Hiroshi (Kanagawa, JP), Hong; WooSang (Gyeonggi-do, KR), Park; MinJeong (Gyeonggi-do, KR), Ono; Yoshiyuki (Shizuoka, JP), Kato; Yasuharu (Shizuoka, JP), Morikami; Kenji (Shizuoka, JP), Emura; Takashi (Shizuoka, JP), Oikawa; Nobuhiro (Kanagawa, JP)
Assignee: Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP)
Application Number:13/377,300
Patent Claim Types:
see list of patent claims
Compound;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Hoffmann-la Roche
ALECENSA
alectinib hydrochloride
CAPSULE;ORAL208434-001Dec 11, 2015RXYesYes9,126,931► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 9,126,931

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2009-139691Jun 10, 2009
PCT Information
PCT FiledJune 09, 2010PCT Application Number:PCT/JP2010/059785
PCT Publication Date:December 16, 2010PCT Publication Number: WO2010/143664

Non-Orange Book Patents for Patent: 9,126,931

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,440,922Tetracyclic compound► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,126,931

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina077025► Subscribe
Australia2010259588► Subscribe
Canada2764653► Subscribe
China102459172► Subscribe
Colombia6430460► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot